Losartan Potassium Tablet, Film Coated
Product Images NDC 55154-2333

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Losartan Potassium (NDC 55154-2333). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Cardinal Health 107, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Losapotatab1 (C516a5a7 Cfc8 4b3b A8bc 7644c3313673 01)

Chemical structure of Losartan Potassium, showing the arrangement of atoms and bonding in the molecule, including a potassium ion (K+) associated with the compound.*

FDA Label Image

Losapotatab2 (C516a5a7 Cfc8 4b3b A8bc 7644c3313673 02)

A line graph comparing the percentage of patients with primary endpoint events over months of study between Atenolol (dashed line) and Losartan Potassium (solid line). The x-axis represents study months (0 to 66), and the y-axis shows the percentage of patients (0 to 16%). The graph includes an adjusted risk reduction of 13% with p=0.021 for Losartan Potassium.*

FDA Label Image

Losapotatab3 (C516a5a7 Cfc8 4b3b A8bc 7644c3313673 03)

A line graph comparing the percentage of patients with fatal or non-fatal stroke over a study period of 66 months. The graph shows two lines: a dashed line for Atenolol and a solid line for Losartan Potassium, with Losartan Potassium associated with a lower percentage of such patients throughout the study. The graph notes an adjusted risk reduction of 25% with a p-value of 0.001.*

FDA Label Image

Losapotatab (C516a5a7 Cfc8 4b3b A8bc 7644c3313673 04)

A forest plot comparing Losartan Potassium and Atenolol event rates for primary composite and stroke (fatal/non-fatal) outcomes across various subgroups including age, gender, race, ischemic heart disease status, diabetes status, and history of cardiovascular disease. The chart displays hazard ratios with 95% confidence intervals and event rates (%) for each group.*

FDA Label Image

Losapotatab5 (C516a5a7 Cfc8 4b3b A8bc 7644c3313673 05)

A line graph depicting the percentage of patients experiencing events over 48 months comparing Losartan Potassium Tablet with placebo. The solid line represents Losartan Potassium, and the dotted line represents placebo, showing a 16.1% risk reduction with a p-value of 0.022.*

FDA Label Image

F3b67cfc 83f1 4210 Bf84 D337ce067349 00

Losartan Potassium Tablets USP 100 mg film-coated oral tablets label shows a 10-tablet unit dose package. The label includes storage instructions, warnings, and pharmacist dispensing requirements. Manufactured by Cadila Healthcare Ltd, India, and distributed by Zydus Pharmaceuticals USA Inc. and Cardinal Health in the USA.*

FDA Label Image

F3b67cfc 83f1 4210 Bf84 D337ce067349 01

Label for Losartan Potassium Tablets USP 50 mg, film-coated oral tablets in a 10-tablet unit dose package. The label includes storage instructions, dispensing warnings, and manufacturing and distribution details from Cardinal Health 107, LLC and other listed companies. It advises pharmacists to dispense with patient information sheet and notes institutional use only and child safety warnings.*

FDA Label Image

F3b67cfc 83f1 4210 Bf84 D337ce067349 02

Losartan Potassium tablets USP 25 mg film-coated tablet label displaying a 10-tablet count. The label includes storage instructions, dispensing warnings, and manufacturer and distributor information including Cardinal Health 107, LLC.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.